Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $17.2 million.

  • Editas Medicine's Cash from Financing Activities changed N/A to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.7 million, marking a year-over-year increase of 755145.91%. This contributed to the annual value of $56.0 million for FY2024, which is 5253.52% down from last year.
  • Latest data reveals that Editas Medicine reported Cash from Financing Activities of $17.2 million as of Q3 2025.
  • Editas Medicine's 5-year Cash from Financing Activities high stood at $261.5 million for Q1 2021, and its period low was -$1.4 million during Q1 2025.
  • In the last 5 years, Editas Medicine's Cash from Financing Activities had a median value of $838000.0 in 2021 and averaged $30.0 million.
  • In the last 5 years, Editas Medicine's Cash from Financing Activities soared by 3192316.08% in 2023 and then tumbled by 84843.75% in 2025.
  • Editas Medicine's Cash from Financing Activities (Quarter) stood at $1.1 million in 2021, then crashed by 41.44% to $619000.0 in 2022, then fell by 16.96% to $514000.0 in 2023, then soared by 10700.19% to $55.5 million in 2024, then plummeted by 69.07% to $17.2 million in 2025.
  • Its Cash from Financing Activities was $17.2 million in Q3 2025, compared to $7.4 million in Q2 2025 and -$1.4 million in Q1 2025.